10-11 is my usual target, but sometimes I get pushback from the patient's pharmacy benefit manager when the Hb exceeds 10, since the FDA-approved label says to taper or discontinue ESA in patients with NDD-CKD when the Hb exceeds 10.
I typically aim for 10-11 once initiated on ESA, but there are nuances based on individual patient factors (symptoms, level of activity, risk of adverse events, etc). I usually do not initiate ESA unless patients have symptoms related to anemia or there is a trend suggesting that Hb will fall below ...
While 10-11 is my usual target, what I aim for var...